lactide structure
|
Common Name | lactide | ||
|---|---|---|---|---|
| CAS Number | 95-96-5 | Molecular Weight | 144.125 | |
| Density | 1.2±0.1 g/cm3 | Boiling Point | 285.5±15.0 °C at 760 mmHg | |
| Molecular Formula | C6H8O4 | Melting Point | 116-119ºC | |
| MSDS | USA | Flash Point | 150.6±18.8 °C | |
| Symbol |
GHS07 |
Signal Word | Warning | |
| Name | 3,6-Dimethyl-1,4-dioxane-2,5-dione |
|---|---|
| Synonym | More Synonyms |
| Density | 1.2±0.1 g/cm3 |
|---|---|
| Boiling Point | 285.5±15.0 °C at 760 mmHg |
| Melting Point | 116-119ºC |
| Molecular Formula | C6H8O4 |
| Molecular Weight | 144.125 |
| Flash Point | 150.6±18.8 °C |
| Exact Mass | 144.042252 |
| PSA | 52.60000 |
| LogP | -1.45 |
| Vapour Pressure | 0.0±0.6 mmHg at 25°C |
| Index of Refraction | 1.429 |
| Storage condition | 2~8℃ |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATA
|
| Symbol |
GHS07 |
|---|---|
| Signal Word | Warning |
| Hazard Statements | H319 |
| Precautionary Statements | P305 + P351 + P338 |
| Personal Protective Equipment | dust mask type N95 (US);Eyeshields;Gloves |
| Hazard Codes | Xi:Irritant; |
| Risk Phrases | R36/37/38 |
| Safety Phrases | S26-S37/39 |
| RIDADR | NONH for all modes of transport |
| WGK Germany | 3.0 |
| RTECS | JH1100000 |
| HS Code | 2934999090 |
| Precursor 10 | |
|---|---|
| DownStream 9 | |
| HS Code | 2934999090 |
|---|---|
| Summary | 2934999090. other heterocyclic compounds. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0% |
|
Magnesium amino-bis(phenolato) complexes for the ring-opening polymerization of rac-lactide.
Dalton Trans. 44 , 12365-75, (2015) Magnesium compounds of tetradentate amino-bis(phenolato) ligands, Mg[L1] (1) and Mg[L2] (2) (where [L1] = 2-pyridyl-N,N-bis(2-methylene-4-methoxy-6-tert-butylphenolato), and [L2] = dimethylaminoethyla... |
|
|
The influence of spray-drying parameters on phase behavior, drug distribution, and in vitro release of injectable microspheres for sustained release.
J. Pharm. Sci. 104(4) , 1451-60, (2015) For ternary solid dispersions, it is indispensable to characterize their structure, phase behavior, and the spatial distribution of the dispersed drug as this might influence the release profile and/o... |
|
|
Microfluidic Synthesis of Hybrid Nanoparticles with Controlled Lipid Layers: Understanding Flexibility-Regulated Cell-Nanoparticle Interaction.
ACS Nano 9 , 9912-21, (2015) The functionalized lipid shell of hybrid nanoparticles plays an important role for improving their biocompatibility and in vivo stability. Yet few efforts have been made to critically examine the shel... |
| L-(-)-Dilactide |
| (3S)-cis-3,6-Dimethyl-1,4-dioxane-2,5-dione |
| L-(-)-Lactide |
| 3,6-Dimethyl-1,4-dioxane-2,5-dione |
| 1,4-Dioxane-2,5-dione, 3,6-dimethyl- |
| EINECS 202-468-3 |
| UNII:7EH08MWO6M |
| L-Lactide |
| MFCD00011685 |
| DL-Lactide |
| lactide |
| (3S,6S)-(-)-3,6-Dimethyl-1,4-dioxane-2,5-dione |
| Propanoic acid, 2-hydroxy-, bimol. cyclic ester |